Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Lymerix Withdrawn: Production Stopped, Inventory To Be Discarded

Executive Summary

GlaxoSmithKline has ceased production of Lymerix and will not be selling its remaining inventory of the Lyme disease vaccine

You may also be interested in...



Lyme Disease Vaccine Pushes Valneva To US Listing

Thomas Lingelbach talks to Scrip about Valneva’s plans for a US IPO to fund Phase III studies of its lead Lyme disease vaccine.

Lyme Disease: Has Big Pharma Stopped The Clock On A Cure?

Though vastly underreported, new cases of Lyme in the US total more than 300,000 a year; its incidence now exceeds infections for far more visible conditions like HIV. A higher profile for Lyme is hobbled by a slow and distorted institutional response, especially among clinicians who disagree on whether Lyme is one disease or a complex constellation of many – much like cancer, but without the commitment.

Lymerix withdrawal update

FDA will update vaccines advisory committee on GlaxoSmithKline's Lymerix during the afternoon of May 21. The company withdrew the lyme disease vaccine Feb. 25, citing low demand. The committee had previously reviewed reports of safety problems with the vaccine (11"The Pink Sheet" March 4, p. 23). The meeting will be held at the Hilton in Silver Spring, Md., at 8:30 a.m...

Related Content

UsernamePublicRestriction

Register

PS039401

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel